Skip to Content

Prevenar

Active Substance: pneumococcal polysaccharide serotype 4 / pneumococcal polysaccharide serotype 6B / pneumococcal polysaccharide serotype 9V / pneumococcal polysaccharide serotype 14 / pneumococcal oligosaccharide serotype 18C / pneumococcal polysaccharide serotype 19F / pneumococcal polysaccharide serotype 23F
Common Name: pneumococcal saccharide conjugated vaccine, adsorbed
ATC Code: J07AL02
Marketing Authorisation Holder: Pfizer Limited
Active Substance: pneumococcal polysaccharide serotype 4 / pneumococcal polysaccharide serotype 6B / pneumococcal polysaccharide serotype 9V / pneumococcal polysaccharide serotype 14 / pneumococcal oligosaccharide serotype 18C / pneumococcal polysaccharide serotype 19F / pneumococcal polysaccharide serotype 23F
Status: Withdrawn
Authorisation Date: 2001-02-02
Therapeutic Area: Pneumococcal Infections Immunization
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Active immunisation against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.

The use of Prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.

The marketing authorisation for Prevenar has been withdrawn at the request of the marketing authorisation holder. 

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide